Inovio Pharmaceuticals (GBM) Stock Price & Analysis
GBM Stock Chart & Stats
- Day’s Range
- EUR 0.75 - EUR 0.76
- 52-Week Range
- EUR 0.56 - EUR 2.18
- Previous Close
- EUR 0.70
- Volume
- 10.38K
- Average Volume (3M)
- 1,174
- Market Cap
- EUR 55.58M
- Enterprise Value
- EUR 61.11M
- Total Cash (Recent Filing)
- EUR 36.67M
- Total Debt (Recent Filing)
- EUR 8.00M
- Price to Earnings (P/E)
- ―
- Beta
- 0.93
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- -0.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress
Completion of late-cycle review and prelicensure inspections represents meaningful progress toward a potential regulatory decision. This reduces some process uncertainty, supports launch planning, and could enable commercialization if the FDA accepts the application and remaining requirements are satisfied.
Platform Validation
Positive pivotal results for a partner’s DNA medicine candidate provide external validation for Inovio’s platform and development approach. Such evidence can strengthen partnering credibility, support future pipeline advancement, and improve the strategic value of related programs.
Cost Discipline And Funding
Lower operating expenses and newly raised capital improve near-term execution capacity by preserving resources for regulatory and launch activities. The stated runway extension gives management additional time to advance INO-3.11k and pursue potential value-creating milestones.
Bears Say
No Meaningful Revenue Base
An effectively zero revenue base shows that Inovio remains dependent on development progress, collaborations, and financing rather than recurring product sales. Persistent losses limit internal reinvestment capacity and make future financial performance highly dependent on successful commercialization.
Cash Burn And Balance-sheet Stress
Ongoing cash consumption combined with sharply reduced equity weakens financial flexibility and increases dependence on external capital. Higher leverage can constrain development and launch decisions, while limited cash generation raises the risk that additional funding will be needed.
Approval And Execution Uncertainty
The unresolved accelerated-approval decision and confirmatory-trial requirements leave the timing and cost of commercialization uncertain. Even with review progress, an unfavorable outcome could delay launch, increase development obligations, and intensify pressure on the company’s limited runway.
GBM FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
What is Inovio Pharmaceuticals’s market cap?
When is Inovio Pharmaceuticals’s upcoming earnings report date?
How were Inovio Pharmaceuticals’s earnings last quarter?
Is Inovio Pharmaceuticals overvalued?
Does Inovio Pharmaceuticals pay dividends?
What is Inovio Pharmaceuticals’s EPS estimate?
How many shares outstanding does Inovio Pharmaceuticals have?
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Inovio Pharmaceuticals Stock Smart Score
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jacqueline E. Shea
- Employees
- 112
- Website
- www.inovio.com
- Address
- 660 West Germantown Pike, Plymouth Meeting, PA, 19462, US
Inovio Pharmaceuticals (GBM) Earnings & Revenues
GBM Company Deck
GBM Earnings Call
Earnings Call SentimentNeutral
The call conveyed meaningful progress on the regulatory front (target PDUFA date, completed inspections, an FDA informal meeting) and tangible commercial/pipeline milestones (partner Phase III success, DPROT preclinical progress, Syneos engagement). Financially the company cut costs and completed an $18.3M equity offering that extends runway into late Q1 2027. However, material risks remain: near‑term liquidity is tight with an $18M projected Q3 burn, net loss improvement was substantially driven by a noncash warrant gain, regulatory uncertainties persist around accelerated approval eligibility and confirmatory trial design feedback, and competitive uptake of a rival product exists. Taken together, positives around regulatory momentum and platform validation are balanced by financing, regulatory, and execution risks.
View all DE:GBM earnings summariesGBM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |